<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438957</url>
  </required_header>
  <id_info>
    <org_study_id>DEX-303</org_study_id>
    <nct_id>NCT01438957</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation</brief_title>
  <official_title>Phase III Randomized Placebo-controlled Double Blind Comparative Study to Investigate the Efficacy and Safety of DA-9501 in Sedation During the Surgery With Epidural Anesthesia or Spinal Anesthesia Without Intubation Under Monitored Sedation Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maruishi Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the efficacy and safety of DA-9501 (Dexmedetomidine)&#xD;
      in patients who require sedation during the surgery that requires epidural or spinal&#xD;
      anesthesia without intubation under monitored sedation care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III, randomized, placebo controlled, double blind, parallel comparative study&#xD;
      (Therapeutic confirmatory trial), to evaluate the efficacy and the safety of Dexmedetomidine&#xD;
      in non-intubated patients who require sedation during surgery with spinal or epidural&#xD;
      anesthesia under monitored sedation care&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2011</start_date>
  <completion_date type="Actual">November 18, 2011</completion_date>
  <primary_completion_date type="Actual">November 18, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration.</measure>
    <time_frame>Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration</measure>
    <time_frame>15 minutes after the start of study drug, if the OAA/S score is 5.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration</measure>
    <time_frame>15 minutes after the start of study drug, if the OAA/S score is 5.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Rescue Administration of Propofol</measure>
    <time_frame>During the study drug infusion period (≥15 minutes [Approximate])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Did Not Require Rescue Administration of Fentanyl During the Study Drug Administration</measure>
    <time_frame>After the surgery start, the administration of fentanyl is permissible as required to treat pain. In case of repeated dose, the dosing interval should be ≥15 minutes.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Fentanyl Dosing Required During the Study Drug Administration.</measure>
    <time_frame>During the study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of Fentanyl Dosing Required During the Study Drug Administration.</measure>
    <time_frame>During the study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent OAA/S Score ≤4 During the Study Drug Infusion</measure>
    <time_frame>Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent OAA/S Score 3 to 4 During the Study Drug Infusion</measure>
    <time_frame>Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Attain the Point Where Patient is Recovered Assessed by Aldrete Score Following Discontinuation of the Study Drug Infusion</measure>
    <time_frame>Every 15 ± 2 minutes until the score of each item becomes ≥1 and the total value becomes ≥8.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Easiness of Maintenance of Sedation Level)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration</time_frame>
    <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Hemodynamic State)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration</time_frame>
    <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Respiratory State)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration</time_frame>
    <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Subject's Cooperation)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration</time_frame>
    <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;I Was Satisfied With This Anesthesia Procedure&quot;)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
    <description>Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;I Did Not Feel Pain During the Surgery&quot;)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
    <description>Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;If You May Undergo a Similar Surgery, the Same Anesthesia Procedure Will be Requested for the Next Time&quot;)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
    <description>Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;Assess the Anxiety Level Before Surgery&quot;)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
    <description>Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;Assess the Anxiety Level During Surgery&quot;)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
    <description>Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;Assess the Anxiety Level After Surgery&quot;)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
    <description>Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.067 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.25 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 0.5 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 1.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine hydrochloride</intervention_name>
    <description>Dexmedetomidine 0.2 to 0.7 mcg/kg/hr</description>
    <arm_group_label>Dexmedetomidine 0.067 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.25 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 0.5 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 1.0 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has signed and dated the Informed Consent after the study had been fully&#xD;
             explained.&#xD;
&#xD;
          2. Patient is male or female, at least 20 years of age when the Informed Consent is&#xD;
             obtained.&#xD;
&#xD;
          3. American Society for Anesthesiologists (ASA) I to III Class.&#xD;
&#xD;
          4. Patient who requires sedation during the elective surgery which requires ≥30mins&#xD;
             (expected time) without intubation under monitored sedation care.&#xD;
&#xD;
          5. Patient undergoing a surgery requiring epidural or spinal anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who underwent general anesthesia within 7 days, or who received other study&#xD;
             drugs within 30 days from the date of consent.&#xD;
&#xD;
          2. Patient with &lt;92% SpO2, at the physical examination prior to the study drug&#xD;
             administration, or ventilatory failure which requires intubation or Laryngeal Mask.&#xD;
&#xD;
          3. Patient with central nervous system pathology which may lead to increased intracranial&#xD;
             pressure, uncontrolled seizures, psychiatric disorder which may be confused with the&#xD;
             response to sedation treatment.&#xD;
&#xD;
          4. Patient who require general anesthesia.&#xD;
&#xD;
          5. Patient who receives treatment by alpha-2 agonists or alpha-2 antagonists within seven&#xD;
             days of scheduled surgery or procedure.&#xD;
&#xD;
          6. Patient in whom opioids, DA-9501 or other alpha-2 agonists, or drugs which may be used&#xD;
             in the study are contraindicated.&#xD;
&#xD;
          7. Patient diagnosed with unstable angina or acute myocardiac infarction within 6 weeks&#xD;
             from the date of consent.&#xD;
&#xD;
          8. Patient whose heart rate is &lt;60 bpm, systolic blood pressure is &lt;90 mmHg by the&#xD;
             physical examination prior to the study drug administration.&#xD;
&#xD;
          9. Patient has third degree heart block, unless the patient has a pacemaker or transverse&#xD;
             pacing wires are in place.&#xD;
&#xD;
         10. Patient who has experienced an increase in alanine transaminase (ALT) and / or&#xD;
             aspartate aminotransferase (AST) more than double the upper normal limit within 2&#xD;
             months of the date of consent, or who has a history of liver insufficiency.&#xD;
&#xD;
         11. Pregnant or lactating woman.&#xD;
&#xD;
         12. In the Investigator's or subinvestigator's opinion, the patient has any symptom or&#xD;
             condition which might increase risk to the patient by conducting the study or preclude&#xD;
             obtaining satisfactory study data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahikawa Medical University Hospital</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sapporo Medical University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kochi Medical School Hospital</name>
      <address>
        <city>Nangoku</city>
        <state>Kochi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshul University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimane University Hospital</name>
      <address>
        <city>Izumo</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Yonago</city>
        <state>Tottori</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kyoto Daini Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miyazaki Hospital</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitano Hospital, The Tazuke Kofukai Medical Research Institute</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <results_first_submitted>January 6, 2021</results_first_submitted>
  <results_first_submitted_qc>March 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2021</results_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Sedation</keyword>
  <keyword>Non-intubation</keyword>
  <keyword>epidural anesthesia</keyword>
  <keyword>spinal anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine 0.067 mcg/kg</title>
          <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="P3">
          <title>Dexmedetomidine 0.25 mcg/kg</title>
          <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="P4">
          <title>Dexmedetomidine 0.5 mcg/kg</title>
          <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="P5">
          <title>Dexmedetomidine 1.0 mcg/kg</title>
          <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="B2">
          <title>Dexmedetomidine 0.067 mcg/kg</title>
          <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="B3">
          <title>Dexmedetomidine 0.25 mcg/kg</title>
          <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="B4">
          <title>Dexmedetomidine 0.5 mcg/kg</title>
          <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="B5">
          <title>Dexmedetomidine 1.0 mcg/kg</title>
          <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="25"/>
            <count group_id="B6" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" lower_limit="51" upper_limit="86"/>
                    <measurement group_id="B2" value="60.7" lower_limit="33" upper_limit="85"/>
                    <measurement group_id="B3" value="63.8" lower_limit="27" upper_limit="86"/>
                    <measurement group_id="B4" value="60.0" lower_limit="28" upper_limit="80"/>
                    <measurement group_id="B5" value="59.3" lower_limit="26" upper_limit="82"/>
                    <measurement group_id="B6" value="62.4" lower_limit="26" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration.</title>
        <time_frame>Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Did Not Require Rescue Administration of Propofol to Achieve and Maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 During the Study Drug Administration.</title>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="7.8" upper_limit="45.4"/>
                    <measurement group_id="O2" value="13.0" lower_limit="2.8" upper_limit="33.6"/>
                    <measurement group_id="O3" value="45.8" lower_limit="25.6" upper_limit="67.2"/>
                    <measurement group_id="O4" value="68.0" lower_limit="46.5" upper_limit="85.1"/>
                    <measurement group_id="O5" value="80.0" lower_limit="59.3" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.086</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Dose-response relationship is assessed using Mantel-extension test. In this analysis, dose of placebo group is hypothesized as 0 microg/kg. Dose-response relationship among Dexmedetomidine 4 dose groups excluding placebo group is also assessed using Mantel-extension test.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel-extension test</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration</title>
        <time_frame>15 minutes after the start of study drug, if the OAA/S score is 5.</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration</title>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Number of dosing</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="4.7"/>
                    <measurement group_id="O2" value="3.7" spread="3.4"/>
                    <measurement group_id="O3" value="1.9" spread="2.3"/>
                    <measurement group_id="O4" value="0.8" spread="1.5"/>
                    <measurement group_id="O5" value="0.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.329</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dosage of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration</title>
        <time_frame>15 minutes after the start of study drug, if the OAA/S score is 5.</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Dosage of Propofol Dosing Required to Achieve and Maintain OAA/S Score ≤4 During the Study Drug Administration</title>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.019" spread="0.933"/>
                    <measurement group_id="O2" value="0.744" spread="0.675"/>
                    <measurement group_id="O3" value="0.373" spread="0.459"/>
                    <measurement group_id="O4" value="0.166" spread="0.298"/>
                    <measurement group_id="O5" value="0.096" spread="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.371</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Rescue Administration of Propofol</title>
        <time_frame>During the study drug infusion period (≥15 minutes [Approximate])</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Rescue Administration of Propofol</title>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" lower_limit="20.0" upper_limit="46.0"/>
                    <measurement group_id="O2" value="20" lower_limit="20.0" upper_limit="22.0"/>
                    <measurement group_id="O3" value="24" lower_limit="21.0" upper_limit="NA">The estimate dose not reach the point of 50%.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="61.0" upper_limit="NA">The estimate dose not reach the point of 50%.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">The estimate dose not reach the point of 50%.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Did Not Require Rescue Administration of Fentanyl During the Study Drug Administration</title>
        <time_frame>After the surgery start, the administration of fentanyl is permissible as required to treat pain. In case of repeated dose, the dosing interval should be ≥15 minutes.</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Did Not Require Rescue Administration of Fentanyl During the Study Drug Administration</title>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="77.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="91.3" lower_limit="72.0" upper_limit="98.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="85.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="96.0" lower_limit="79.6" upper_limit="99.9"/>
                    <measurement group_id="O5" value="96.0" lower_limit="79.6" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.869</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Fentanyl Dosing Required During the Study Drug Administration.</title>
        <time_frame>During the study drug administration</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Fentanyl Dosing Required During the Study Drug Administration.</title>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Number of dosing</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.6"/>
                    <measurement group_id="O2" value="0.2" spread="0.7"/>
                    <measurement group_id="O3" value="0.0" spread="0.0"/>
                    <measurement group_id="O4" value="0.0" spread="0.2"/>
                    <measurement group_id="O5" value="0.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.897</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dosage of Fentanyl Dosing Required During the Study Drug Administration.</title>
        <time_frame>During the study drug administration</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Dosage of Fentanyl Dosing Required During the Study Drug Administration.</title>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>mcg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.068" spread="0.320"/>
                    <measurement group_id="O2" value="0.085" spread="0.317"/>
                    <measurement group_id="O3" value="0.000" spread="0.000"/>
                    <measurement group_id="O4" value="0.018" spread="0.088"/>
                    <measurement group_id="O5" value="0.061" spread="0.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.897</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent OAA/S Score ≤4 During the Study Drug Infusion</title>
        <time_frame>Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent OAA/S Score ≤4 During the Study Drug Infusion</title>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.17" spread="23.88"/>
                    <measurement group_id="O2" value="58.15" spread="20.71"/>
                    <measurement group_id="O3" value="61.44" spread="18.28"/>
                    <measurement group_id="O4" value="70.07" spread="21.08"/>
                    <measurement group_id="O5" value="76.78" spread="14.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.116</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent OAA/S Score 3 to 4 During the Study Drug Infusion</title>
        <time_frame>Pre-dose, every 5 ± 2 minutes after start of study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent OAA/S Score 3 to 4 During the Study Drug Infusion</title>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.88" spread="25.31"/>
                    <measurement group_id="O2" value="56" spread="19.87"/>
                    <measurement group_id="O3" value="53.66" spread="17.5"/>
                    <measurement group_id="O4" value="65.3" spread="20.63"/>
                    <measurement group_id="O5" value="62.25" spread="23.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Attain the Point Where Patient is Recovered Assessed by Aldrete Score Following Discontinuation of the Study Drug Infusion</title>
        <time_frame>Every 15 ± 2 minutes until the score of each item becomes ≥1 and the total value becomes ≥8.</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Attain the Point Where Patient is Recovered Assessed by Aldrete Score Following Discontinuation of the Study Drug Infusion</title>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="NA" upper_limit="NA">There were a lot of tied values of the median in individual data, the 95% CI could not be calculated (could not become an interval).</measurement>
                    <measurement group_id="O2" value="15" lower_limit="NA" upper_limit="NA">There were a lot of tied values of the median in individual data, the 95% CI could not be calculated (could not become an interval).</measurement>
                    <measurement group_id="O3" value="15" lower_limit="15.0" upper_limit="16.0"/>
                    <measurement group_id="O4" value="15" lower_limit="NA" upper_limit="NA">There were a lot of tied values of the median in individual data, the 95% CI could not be calculated (could not become an interval).</measurement>
                    <measurement group_id="O5" value="15" lower_limit="NA" upper_limit="NA">There were a lot of tied values of the median in individual data, the 95% CI could not be calculated (could not become an interval).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Easiness of Maintenance of Sedation Level)</title>
        <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
        <time_frame>Within 24 hours after completion of the study drug administration</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Easiness of Maintenance of Sedation Level)</title>
          <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.85" spread="3.54"/>
                    <measurement group_id="O2" value="4.36" spread="3.41"/>
                    <measurement group_id="O3" value="3.73" spread="3.19"/>
                    <measurement group_id="O4" value="2.81" spread="2.64"/>
                    <measurement group_id="O5" value="2.65" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Hemodynamic State)</title>
        <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
        <time_frame>Within 24 hours after completion of the study drug administration</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Hemodynamic State)</title>
          <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="2.21"/>
                    <measurement group_id="O2" value="3.3" spread="3.19"/>
                    <measurement group_id="O3" value="1.68" spread="1.46"/>
                    <measurement group_id="O4" value="1.72" spread="2.14"/>
                    <measurement group_id="O5" value="1.47" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.737</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Respiratory State)</title>
        <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
        <time_frame>Within 24 hours after completion of the study drug administration</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Stability of Respiratory State)</title>
          <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="2.77"/>
                    <measurement group_id="O2" value="2.62" spread="2.79"/>
                    <measurement group_id="O3" value="1.8" spread="2.02"/>
                    <measurement group_id="O4" value="2.85" spread="2.9"/>
                    <measurement group_id="O5" value="3.12" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Subject's Cooperation)</title>
        <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
        <time_frame>Within 24 hours after completion of the study drug administration</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale (VAS) Score Evaluation by Investigator or Sub-investigator (Subject's Cooperation)</title>
          <description>VAS score ranges from 0 to 10, with 0 being the better/preferred outcome. Low values indicated more ease of maintenance of sedation level.</description>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="1.67"/>
                    <measurement group_id="O2" value="1.8" spread="2.35"/>
                    <measurement group_id="O3" value="1.05" spread="1.46"/>
                    <measurement group_id="O4" value="1.15" spread="1.19"/>
                    <measurement group_id="O5" value="1.17" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.567</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;I Was Satisfied With This Anesthesia Procedure&quot;)</title>
        <description>Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.</description>
        <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;I Was Satisfied With This Anesthesia Procedure&quot;)</title>
          <description>Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.</description>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.8"/>
                    <measurement group_id="O2" value="1.7" spread="1"/>
                    <measurement group_id="O3" value="1.2" spread="0.4"/>
                    <measurement group_id="O4" value="1.4" spread="0.7"/>
                    <measurement group_id="O5" value="1.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.234</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;I Did Not Feel Pain During the Surgery&quot;)</title>
        <description>Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.</description>
        <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;I Did Not Feel Pain During the Surgery&quot;)</title>
          <description>Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.</description>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.7"/>
                    <measurement group_id="O2" value="1.2" spread="0.7"/>
                    <measurement group_id="O3" value="1.2" spread="0.7"/>
                    <measurement group_id="O4" value="1.4" spread="0.9"/>
                    <measurement group_id="O5" value="1.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.729</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;If You May Undergo a Similar Surgery, the Same Anesthesia Procedure Will be Requested for the Next Time&quot;)</title>
        <description>Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.</description>
        <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;If You May Undergo a Similar Surgery, the Same Anesthesia Procedure Will be Requested for the Next Time&quot;)</title>
          <description>Rating: 1 is the better/preferred value for scores from 1 to 4. Low values indicated more ease of maintenance of sedation level.</description>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.1"/>
                    <measurement group_id="O2" value="1.5" spread="0.8"/>
                    <measurement group_id="O3" value="1.3" spread="0.6"/>
                    <measurement group_id="O4" value="1.5" spread="0.8"/>
                    <measurement group_id="O5" value="1.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;Assess the Anxiety Level Before Surgery&quot;)</title>
        <description>Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.</description>
        <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;Assess the Anxiety Level Before Surgery&quot;)</title>
          <description>Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.</description>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.3"/>
                    <measurement group_id="O2" value="2.2" spread="1.3"/>
                    <measurement group_id="O3" value="2.2" spread="1.2"/>
                    <measurement group_id="O4" value="1.8" spread="1"/>
                    <measurement group_id="O5" value="2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.451</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;Assess the Anxiety Level During Surgery&quot;)</title>
        <description>Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.</description>
        <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;Assess the Anxiety Level During Surgery&quot;)</title>
          <description>Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.</description>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.1"/>
                    <measurement group_id="O2" value="1.6" spread="0.8"/>
                    <measurement group_id="O3" value="1.6" spread="0.9"/>
                    <measurement group_id="O4" value="1.4" spread="0.9"/>
                    <measurement group_id="O5" value="1.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.873</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;Assess the Anxiety Level After Surgery&quot;)</title>
        <description>Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.</description>
        <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
        <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine 0.067 mcg/kg</title>
            <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O3">
            <title>Dexmedetomidine 0.25 mcg/kg</title>
            <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O4">
            <title>Dexmedetomidine 0.5 mcg/kg</title>
            <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
          <group group_id="O5">
            <title>Dexmedetomidine 1.0 mcg/kg</title>
            <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Score Evaluation of Satisfaction and Anxiety of the Subject (&quot;Assess the Anxiety Level After Surgery&quot;)</title>
          <description>Rating: 1 is the better/preferred value for scores from 1 to 5. Low values indicated more ease of maintenance of sedation level.</description>
          <population>Full Analysis Set&lt;FAS&gt;: FAS is defined as all patients who were administered with the study drugs.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.9"/>
                    <measurement group_id="O2" value="1.6" spread="1"/>
                    <measurement group_id="O3" value="1.6" spread="0.6"/>
                    <measurement group_id="O4" value="1.3" spread="0.7"/>
                    <measurement group_id="O5" value="1.5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The closed testing procedure is used taking multiplicity into consideration, in which Dexmedetomidine 1.0 mcg/kg group, 0.5 mcg/kg group, 0.25 mcg/kg group, 0.067 mcg/kg group and the placebo group are tested in this order</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.374</p_value>
            <method>Mantel Haenszel</method>
            <method_desc>Stratified by the anesthesia type</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events that occurred from the start of treatment to 24 hours after the end of treatment, a median of 67 - 87 mins treatment depending on treatment arms.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>0 mcg/kg/hr 10min Initial dose + 0 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="E2">
          <title>Dexmedetomidine 0.067 mcg/kg</title>
          <description>0.4 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="E3">
          <title>Dexmedetomidine 0.25 mcg/kg</title>
          <description>1.5 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="E4">
          <title>Dexmedetomidine 0.5 mcg/kg</title>
          <description>3 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
        <group group_id="E5">
          <title>Dexmedetomidine 1.0 mcg/kg</title>
          <description>6 mcg/kg/hr 10min Initial dose + 0.2-0.7 mcg/kg/hr Maintenance dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Glossoptosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bladder irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythemas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasculitides</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator publishes any results of this study, a pre-publication manuscript shall be provided the sponsor for review at least 60 days prior to the submission of the manuscript to the publisher.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

